Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Operating Leases came in at $1.1 million in Q1 2026, down 0.95% YoY from $1.2 million in Q1 2025, and up 33.53% on a QoQ basis from $859000.0 in Q4 2025.
Zevra Therapeutics (ZVRA) Operating Leases (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of Operating Leases data on file, last reported at $1.1 million in Q1 2026.
- Quarterly Operating Leases fell 0.95% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 0.95% YoY) and the FY2025 annual result came in at $859000.0, up 8.46% from the prior year.
- Operating Leases rose to $1.1 million in Q1 2026, from $859000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $1.6 million in Q2 2025 to a low of $456000.0 in Q4 2023.
- A 5-year average of $941153.8 and a median of $859000.0 in 2025 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases plunged 46.91% — and 2025, when it surged 191.3%.
- Tracing ZVRA's Operating Leases over 5 years: stood at $843000.0 in 2022, then slumped by 45.91% to $456000.0 in 2023, then surged by 73.68% to $792000.0 in 2024, then gained by 8.46% to $859000.0 in 2025, then jumped by 33.53% to $1.1 million in 2026.
- The last three Operating Leases figures came in at $1.1 million (Q1 2026), $859000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | 1.15 Mn |
| Dec 31, 2025 | 859,000.00 |
| Sep 30, 2025 | 1.41 Mn |
| Jun 30, 2025 | 1.58 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 792,000.00 |
| Sep 30, 2024 | 483,000.00 |
| Jun 30, 2024 | 1.14 Mn |
| Mar 31, 2024 | 705,000.00 |
| Dec 31, 2023 | 456,000.00 |
| Sep 30, 2023 | 517,000.00 |
| Dec 31, 2022 | 843,000.00 |
| Mar 31, 2022 | 1.14 Mn |
| Dec 31, 2021 | 1.59 Mn |
| Sep 30, 2021 | 1.67 Mn |
| Jun 30, 2021 | 1.41 Mn |
| Mar 31, 2021 | 1.50 Mn |
| Dec 31, 2020 | 1.59 Mn |
| Sep 30, 2020 | 1.99 Mn |